Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes symptomatic deep vein thrombosis compared with no prophylaxis (very low certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher minor bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Quality of life ‐ not reported · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional outcomes · acute ischaemic stroke
Endovascular thrombectomy interventions leads to higher favourable functional outcome at the end of compared with standard therapy (high certainty).
1 finding from 1 review
Death from all causes at the end of · acute ischaemic stroke
Endovascular thrombectomy interventions leads to lower death from all causes at the end of compared with standard therapy (high certainty).
1 finding from 1 review
Symptomatic intracranial haemorrhage at · acute ischaemic stroke
Endovascular thrombectomy interventions showed no clear difference in symptomatic intracranial haemorrhage at the end of compared with standard therapy (high certainty).
1 finding from 1 review
Neurological status · acute ischaemic stroke
Endovascular thrombectomy interventions probably leads to higher neurological status at the end of compared with standard therapy (moderate certainty).
1 finding from 1 review
Degree of recanalisation (TIMI grade) · acute ischaemic stroke
Endovascular thrombectomy interventions probably leads to higher degree of recanalisation (TIMI grade) compared with standard therapy (moderate certainty).
1 finding from 1 review
Remission (response plus end score 8 or less) · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes remission (response plus end score 8 or less) compared with light therapy (very low certainty).
1 finding from 1 review
Speed of onset of response · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ treatment emergent · adults with seasonal affective disorder
Fluoxetine showed no clear difference in adverse events (at least 1 treatment‐emergent adverse event) compared with light therapy (low certainty).
1 finding from 1 review
Response (> 50% improvement on 24‐item HAM‐D SIGH‐SAD) · adults with seasonal affective disorder
Fluoxetine showed no clear difference in response (> 50% improvement on 24‐item HAM‐D SIGH‐SAD) compared with light therapy (low certainty).
1 finding from 1 review
Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (SF‐20 & Q‐LES‐Q) Eight weeks · adults with seasonal affective disorder
1 finding from 1 review
Moderate or severe OHSS · women undergoing assisted reproduction
Dopamine agonist probably leads to lower incidence of moderate or severe OHSS compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Multiple pregnancy rate · women undergoing assisted reproduction
It is very uncertain whether dopamine agonist plus co‐intervention changes multiple pregnancy rate compared with co‐intervention (very low certainty).
1 finding from 1 review
Miscarriage · women undergoing assisted reproduction
Dopamine agonist plus co‐intervention showed no clear difference in miscarriage rate compared with co‐intervention (low certainty).
1 finding from 1 review
Any other adverse events · women undergoing assisted reproduction
It is very uncertain whether dopamine agonist plus co‐intervention changes any other adverse events compared with co‐intervention (very low certainty).
1 finding from 1 review